Colleen S. Limegrover

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

Nicholas J. Izzo, Carla M. Yuede, Kelsie M. LaBarbera et al. · Alzheimer s & Dementia · 2021 · 97 citations · Full text

Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein

Colleen S. Limegrover, Raymond Yurko, Nicholas J. Izzo et al. · Journal of Neuroscience Research · 2021 · 40 citations · Full text

Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease

Gilbert M. Rishton, Gary C. Look, Zhi‐Jie Ni et al. · ACS Medicinal Chemistry Letters · 2021 · 40 citations · Full text

Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity

Colleen S. Limegrover, Harry LeVine, Nicholas J. Izzo et al. · Journal of Neurochemistry · 2020 · 27 citations · Full text

Modeling the mature CNS: A predictive screening platform for neurodegenerative disease drug discovery

Kelsie M. LaBarbera, Colleen S. Limegrover, Courtney Rehak et al. · Journal of Neuroscience Methods · 2021 · 10 citations · Full text